NEW YORK (GenomeWeb) – Guardant Health said today that Medicare contractor Palmetto GBA has finalized its local coverage determination for the Guardant360 liquid biopsy assay in non-small cell lung cancer.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have an account?
Login Now.